Saxenda Reviews 2026: What Real Users Are Actually Saying

Saxenda at a glance:

• Drug class: GLP-1 receptor agonist
• Manufacturer: Novo Nordisk
• FDA approved: 2014
• Route: subcutaneous injection (multi-dose pen)
• Typical frequency: once daily
• Half-life: approximately 13 hours
• Cash price (US): $1,200-$1,400/month without insurance
• Receptor target: GLP-1 receptor

Online reviews are a flawed source. They overrepresent quitters and dramatic stories, and they underrepresent quiet long-term satisfaction. Read with that in mind, Saxenda reviews still tell you something useful.

What Users Praise

Across patient communities, the most consistent positive reports about Saxenda:

• The intended effect works. Users who reach maintenance dose and stay on it generally report meaningful change.
• Reduced food noise. A specific phrase users return to repeatedly — the cognitive load of food planning drops.
• Manageable routine. once daily dosing fits into ordinary life.

What Users Complain About

The complaint clusters are equally consistent:

• Side effects during titration. Most prominent in the first 4-8 weeks; usually improve at steady dose.
• Cost. $1,200-$1,400/month without insurance is a meaningful barrier for many users without insurance coverage.
• Supply / availability. Periodic shortages have affected GLP-1 medications since 2022.
• Plateau or response variability. Not everyone gets the trial-average response.

Patterns of Discontinuation

The most common reasons users report stopping Saxenda:

1. Cost or coverage change — accounts for the largest share of discontinuations
2. Side effects that don't improve at steady dose — minority of users
3. Reaching a target and choosing to taper — usually with mixed results long-term
4. Switching to a different agent — often based on prescriber recommendation

How to Read User Reviews

A few caveats worth keeping in mind when reading reviews of Saxenda:

• People who quit are overrepresented in negative reviews; long-term satisfied users post less
• Side-effect descriptions are often most prominent during the first weeks of titration
• Cost complaints reflect insurance and program eligibility — your situation may differ
• "Did it work?" is often answered before the maintenance dose is reached

What the Trials Add

Trial data cuts through some of the noise. SCALE Obesity (Pi-Sunyer 2015, NEJM) — 9.2% mean weight loss vs 3.5% placebo at 56 weeks. Mean weight loss of 8% of body weight at 56 weeks in SCALE trials — modest compared with semaglutide or tirzepatide.

For deeper trial detail, see our Saxenda results page.

Comparing to Alternatives

When users compare Saxenda to alternatives, the head-to-head reviews tend to favor newer, more potent agents on efficacy and longer-acting agents on convenience. Most patients now choose Wegovy or Zepbound over Saxenda for greater weight loss with weekly (rather than daily) dosing.

Bottom Line

Don't let online reviews talk you out of Saxenda (or into it). They capture real experience but with serious selection bias.

Frequently Asked Questions

Related Reading

• Saxenda Explained: How It Works and Who It's For
• Saxenda Side Effects Decoded: What's Normal vs. What Isn't
• Does Saxenda Really Work? An Evidence-Based Results Review
• Saxenda Price Decoded: Insurance, Coupons, and Cash-Pay Options
• What Is Ozempic? Everything You Should Know Before Starting
• Is Ozempic Safe? An Honest Look at the Side-Effect Profile

Sources

• Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE). NEJM 2015;373:11.
• Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM 2023;389:2221.
• Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989.

User reports are anecdotal and don't substitute for trial data or clinical guidance.